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E-mail address: ichi@oist.jp (I.N. Maruyama).The tropomyosin-related kinase A (TrkA) receptor and its ligand, nerve growth factor (NGF), play
crucial roles in the development and function of the nervous system. NGF is believed to activate
TrkA by bridging two TrkA monomers, leading to TrkA transphosphorylation. However, here we
show that the majority of TrkA receptors exist as preformed, yet inactive, homodimers prior to
NGF binding by using three different approaches such as chemical crosslinking and enzyme frag-
ment complementation assay. Furthermore, TrkA homodimers are formed in endoplasmic reticu-
lum before newly synthesized receptors reach the cell surface. These ﬁndings shed light on
molecular mechanisms underlying transmembrane signaling by TrkA.
Structured summary:
TrkA physically interacts with TrkA by protein complementation assay (View interaction)
TrkA physically interacts with TrkA by bimolecular ﬂuorescence complementation (View interaction)
TrkA physically interacts with TrkA by cross-linking study (View interaction)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction However, it was found that NGF mimetics and Fab fragments ofThe tropomyosin-related kinase A (TrkA) receptor is amember of
the neurotrophin tyrosine kinase receptor family, and consists of an
extracellular ligand-binding domain, a single transmembrane do-
main and an intracellular tyrosine kinase domain. After binding to
its ligand, nerve growth factor (NGF), TrkA is activated and initiates
a signalling cascade of molecules including Ras/Raf/MAP kinase,
PI3K/Akt, and PLC-c [1–3]. It is believed that TrkA is activated by
NGF-induced receptor dimerization. Crosslinking studies revealed
that [125I] NGF could bind both TrkA monomer and homodimer
[4,5]. Because NGF exists in solution as a stable homodimer [6], it
is thought that a single NGF dimer acts as a bridge to induce
dimerization of two TrkAmonomers [7]. This model was supported
by the crystal structure of NGF bound to the ligand-binding
immunoglobulin domains of TrkA, which has been shown to have
a symmetric 2:2 stoichiometry of the complex [8].chemical Societies. Published by E
ﬂuorescence complementa-
FR, epidermal growth factor
lonal antibody; NGF, nerve
essing Biology Unit, Okinawa
nna, Kunigami, Okinawa 904-monoclonal antibody (mAb) against TrkA, which are incapable of
forming dimers, can activate TrkA [9,10]. Moreover, an asymmetric
chimeric NGF/Neurotrophin-4 heterodimer was also found to acti-
vate TrkA [11]. These studies suggest that the ligand binding may
not be responsible for the receptor dimerization. Further, Mischel
et al. [12] concluded that the TrkA receptors exist as oligomers in
the plasma membrane prior to NGF binding, when ectopically ex-
pressed in Xenopus leavis oocytes. In the present study, we have
shown that TrkA exists as a preformed, yet inactive, dimer in living
cells by using three different approaches, chemical crosslinking,
bimolecular ﬂuorescence complementation (BiFC), and ﬁreﬂy lucif-
erase fragment complementation. We have also found that TrkA
spontaneously dimerizes in endoplasmic reticulum (ER) before it
reaches the cell surface.2. Materials and methods
2.1. Plasmid construction
BiFC vectors, pBiFC-VN173 and pBiFC-VC155, were described
previously [13,14]. From the vector pBiFC-VN173, a DNA fragment
encoding a FLAG tag was removed to prevent the tag fusions
with TrkA by synthesizing a Sac I-Eco RI fragment from a pair
of oligonucleotides, 50-GCAGAGCTCGTTTAGTGAACCGTCAGAATTGlsevier B.V. All rights reserved.
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now enzyme, and then by inserting the fragment between Sac I
and Eco RI of the vector. Likewise, a HA tag was removed by synthe-
sizing an Apa I-Eco RI fragment from a pair of oligonucleotides, 50-
CCGCGGGCCCACCATAGCTCG and 50-GACCGAATTCGAGCTATGGTG-
GG, and then by inserting the resulting fragment into pBiFC-VC155.
PCR products which encode a full-length human TrkA protein were
ampliﬁed using pLNCX-hTrkA [15,16], a generous gift fromDr. Garret
M. Brodeur (Children’s Hospital of Philadelphia, PA, USA), as a
template and the following primer pairs: 50-CCGGAATTCACCATG-
CTGCGAGGCGGACGGCG (TrkA-VN173-F) and 50-GCTCTAGAGCCC-
AGGACATCCAGGTAGAC (TrkA-VN173-R), or 50-CCGGAATTCAC-
CATGCTGCGAGGCGGACGGCG (TrkA-VC155-F) and 50-CCGCTCGA-
GAGCCCAGGACATCCAGGTAGAC (TrkA-VC155-R). The PCR prod-
ucts were inserted between EcoRI and XbaI sites of pBiFC-VN173,
or between EcoRI and XhoI of pBiFC-VC155, resulting in pTrkA-VN
or pTrkA-VC, respectively. After the construction, synthetic dou-
ble-stranded oligonucleotides encoding GGGSGGGSGGGS, which
was termed (G4S)3, were inserted into the unique XbaI or XhoI site
of pBiFC-VN173 or pBiFC-VC155, respectively.
To construct plasmids for ﬁreﬂy (Photinus pyralis) luciferase
fragment complementation, a DNA fragment encoding the N-ter-
minal fragment (aa 2–416) or C-terminal fragment (aa 398–550)
of the luciferase was ampliﬁed from FRB-NLuc or CLuc-FKBP, gen-
erous gifts from Dr. David Piwnica-Worms (Washington University
School of Medicine, St. Louis, MO, USA) with the following primer
pairs, respectively: 50-CCTCTAGAGGTGGTGGTGGTTCTGGTGGTGG
TGGTTCTGGTGGTGGTGGTTCTGAAGACGCCAAAAACATAAAGAAAGG
CCCG [XbaI-(G4S)3-NLuc-F] and 50-CCCTCGAGTCATCCATCCTTGTC
AATCAAGGCGTTGGTCGCTTCCGGATTGTTTACATAACC (XhoI-NLuc-R),
or 50-CCTCTAGAGGTGGTGGTGGTTCTGGTGGTGGTGGTTCTGGTGGT
GGTGGTTCTATGTCCGGTTATGTAAACAATCCGGAAGCGA [XbaI-(G4S)
3-CLuc-F] and 50-CCCTCGAGTCACACGGCGATCTTTCCGCCCTTCTT
GG (XhoI-CLuc-R). The two PCR products were inserted between
XbaI and XhoI of pBiFC-VN173, resulting in pBiFC-NLuc and
pBiFC-CLuc, respectively. Then, a DNA fragment encoding TrkA
was cut out with EcoRI and XbaI from pTrkA-VN, and was inserted
into the pBiFC-NLuc and pBiFC-CLuc, resulting in pTrkA-NLuc and
pTrkA-CLuc, respectively. The validity of all the constructs was
conﬁrmed by DNA sequencing and Western blotting.
2.2. Cell culture
The human embryonic kidney (HEK) 293 cell line and the rat
pheochromocytoma PC12 cell line were purchased from RIKEN Cell
Bank (Ibaraki, Japan). The former was maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Nacalai Tesque, Kyoto, Japan)
supplemented with 10% fetal bovine serum (FBS; Invitrogen KK,
Tokyo, Japan). The latter was maintained in DMEM supplemented
with5%FBSand10%horse serum.All the culturemediawere supple-
mented with 100-U/ml penicillin/streptomycin (Nacalai Tesque).
2.3. Chemical crosslinking
PC12 cells were cultured to a concentration of 1.0  107cells/
dish (10 cm in diameter; Iwaki Asahi Techno Glass, Chiba, Japan)
before chemical crosslinking. The cells were serum-starved for
3 h at 37 C, and incubated in DMEM containing 0.45 M sucrose
for 20 min at 37 C. Cells were treated with or without 100 ng/ml
NGF at 37 C for 5 min, followed by washing twice with Dulbecco’s
phosphate-buffered saline (DPBS; Invitrogen), which contains
0.45 M sucrose. Then, cells were treated with or without 1.0 mM
BS3 (Pierce Biotechnology, Rochford, IL, USA) in DPBS, which con-
tained 0.45 M sucrose, for 20 min at 37 C. This crosslinking reac-
tion was quenched by adding 40 mM Tris–HCl, pH 8.0, and
0.45 M sucrose at ﬁnal concentrations, followed by incubating for15 min at room temperature. After being washed twice with ice-
cold DPBS, the cells were lysed with NP40 lysis buffer (50 mM
Tris–HCl, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1.0 mM
Na3VO4, 1% Nonidet P-40) supplemented with a protease inhibitor
cocktail (1; Nakalai Tesque) and a phosphatase inhibitor cocktail
(1; Nacalai Tesque) for 30 min at 4 C. Resulting cell lysates were
sonicated twice for 5 s each, and centrifuged at 10 000 rpm for
10 min at 4 C. The supernatants were collected for Western
blotting.
2.4. Western blotting
Western blotting was performed as previously described [14].
The following primary antibodies were used: Polyclonal antibody
against TrkA (Acris Antibodies, Herford, Germany), mouse mAb
against TrkA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit
polyclonal antibody against Trk (Santa Cruz Biotechnology), rabbit
mAb against phospho-TrkA (Tyr490), rabbit mAb against phospho-
TrkA (Tyr 674/675) (Cell Signaling Technology, Japan, Tokyo), rabbit
mAb against p44/42 MAP kinase (Cell Signaling Technology), and
rabbit mAb against phospho-p44/42 MAPK (Thr202/Tyr204) (Cell
Signaling Technology).
2.5. Immunoﬂuorescent staining
Immunoﬂuorescent staining was performed as previously de-
scribed [14]. Cells were incubated with the following antibodies:
Primary antibodies, rabbit mAb against phospho-TrkA (Tyr490)
(Cell Signaling Technology) and rabbit anti-calnexin antibody (Sig-
ma-Aldrich Japan, Tokyo); and secondary antibody, Alexa Fluor
633-conjugated goat anti-rabbit IgG (H+L) antibody (Molecular
Probes, Eugene, OR, USA). HEK293 cells co-expressing TrkA-VN
and TrkA-VC were treated with (+) or without () 10 lg/ml Brefel-
din A (BFA) for 12 h at 37 C.
2.6. Fireﬂy luciferase fragment complementation
HEK293 cells were plated in a 96-well black polystyrene boro-
silicate glass microplate (Iwaki) at a concentration of 8  103
cells/well 12 h before transfection. Then the cells were transfected
with 25 ng pGL3 (Promega, Madison, WI, USA), which encoded a
full-length luciferase, or 100 ng of expression plasmid constructs
by using 0.1 ll Plus Reagent (Invitrogen) and 0.25 ll Lipofectamin
LTX Reagent (Invitrogen) in 20 ll Opti-MEM I reduced serummed-
ium (Invitrogen). Forty-hours after transfection, the cells were ser-
um-starved for 3 h, washed once with DPBS, and then incubated
for 10 min at room temperature in 100 ll DPBS containing
0.15 mg/ml D-luciferin (Promega). The cells were also treated with
50 ng/ml or 100 ng/ml NGF for 5 min at 37 C before the incubation
with luciferin as indicated. Then bioluminescence was measured
by using LAS 3000 (Fujiﬁlm, Tokyo, Japan). The bioluminescence
intensity was also measured by using a microplate luminometer,
LB 960 Centro (Berthold Japan, Osaka). Data were collected from
three independent, quadruplicate experiments, and are presented
as the mean ± S.D. Statistical signiﬁcance was assessed using one-
tailed Student’s t-test. The P values less than 0.01 were assessed
to be statistically signiﬁcant.3. Results
3.1. Preformed TrkA homodimers detected by chemical crosslinking
To examine whether TrkA receptor exists as a preformed
homodimer on the cell surface, we tried to chemically crosslink
the receptors on the surface of PC12 cells, which endogenously
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for 3 h, and then treated with BS3, a membrane-impermeable cross-
linker, after being incubated with or without NGF. Sucrose, 0.45 M
at a ﬁnal concentration, was added to the culture media in order to
inhibit the clathrin-dependent endocytosis of TrkA upon NGF bind-
ing [18,19]. The cell lysates were subjected toWestern blotting, and
immunostained with anti-TrkA antibody. In the presence of the
crosslinker, both of lower molecular weight molecules, at 110 and
140 kDa, and higher molecular weight molecule, at280 kDa, were
recognized by anti-TrkA antibody, while in the absence of the cross-
linker, only the lower molecular weight molecules were detected
(Fig. 1). Based on the apparent molecular weights, protein bands
with the lower and higher molecular weights are assigned as
monomeric and dimeric forms of TrkA, respectively. The lower
molecular weight bands, 110 and 140 kDa, correspond to partially
N-glycosylated and fully glycosylated forms, respectively [20,21].
The band intensity of the TrkA dimer cross-linked was similar in
the absence and presence of NGF. This result indicates that a frac-
tion of TrkA exists as a preformed dimer, and that the dimer fraction
is not increased after being incubated with NGF. However, a large
fraction of TrkA existed as a monomer even after the chemical
crosslinking. This suggested that only a small fraction of the recep-
tors existed as dimers on the cell surface and a large fraction of the
receptors were present inside the cell, or that a large fraction of
TrkA receptors existed as monomers on the cell surface and the
chemical crosslinking reaction was inefﬁcient to bridge two
receptors induced by ligand binding. To distinguish these two pos-
sibilities, we tried to observe TrkA expressed in living cells by
ﬂuorescence microscopy as described below.
3.2. Fluorescence microscopic observation of preformed TrkA
homodimers
To directly observe the TrkA dimerization and their subcellular
localization in living cells, we employed BiFC [14,22]. ThisNGF
BS3
- + - +- - + +
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kDa
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IB: α-TrkA
IB: α-pMAPK
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Fig. 1. Chemical crosslinking of endogenous TrkA on the PC12 cell surface. PC12
cells were stimulated with (+) or without () 100 ng/ml NGF, and then treated with
(+) or without () BS3. The cells were lysed and subjected to Western blotting,
followed by immunoblotting (IB) with anti-TrkA antibody. The positions of TrkA
monomer and dimer are indicated by ﬁlled and open arrows, respectively, on the
right margin. The positions of molecular weight standards are also shown on the
left. The Western blot was also immunostained with anti-p44/42 MAP kinase (a-
MAPK), anti-phospho-p44/42 MAP kinase (a-pMAPK), or anti-tubulin (a-Tublin)
antibody. This ﬁgure represents three similar independent results.technique is based on the reconstitution of a ﬂuorescent protein
complex from two separate non-ﬂuorescent fragments, which is
induced by the association of two interacting partners fused to
the fragments. We fused the N-terminal and C-terminal fragments
of the Venus ﬂuorescent protein [23], a derivative of yellow ﬂuo-
rescent protein, to the C-terminus of TrkA, separately. When the
two fusion receptors TrkA-VN and TrkA-VC were co-expressed in
HEK293 cells, the receptor autophosphorylation was observed to
be at a basal level (Supplementary Fig. S1A). When the cells were
stimulated with NGF, the phosphorylation levels of the fusion
receptors were markedly enhanced, indicating that the fusion
receptors behave like the wild-type receptor. Venus ﬂuorescence
was clearly observed in HEK293 cells co-expressing TrkA-VN and
TrkA-VC (Fig. 2A, left), whereas no ﬂuorescence was observed in
HEK293 cells expressing either TrkA-VN or TrkA-VC, or in cells
co-expressing TrkA-VC and ErbB3-VN as a negative control (Sup-
plementary Fig. S1B). These results indicate that TrkA spontane-
ously dimerizes in the absence of NGF. Moreover, the fusion
receptors were phosphorylated upon NGF binding when analyzed
by immunostaining (Fig. 2A, middle), indicating that TrkA exists
as an inactive dimer, which can be activated by NGF binding.Fig. 2. BiFC assay of TrkA homodimers. (A) HEK293 cells co-expressing TrkA-VN
and TrkA-VC were treated with (+) or without () 100 ng/ml NGF. The cells were
ﬁxed, and immunostained with anti-pTrkA primary antibody and then with
ﬂuorescently labeled secondary antibody. Fluorescence signals of Venus (green)
and pTrkA (red) were observed by confocal microscopy. Note that the green and red
ﬂuoresce images do not completely overlap since some cells express only one of the
two constructs. This ﬁgure represents >20 similar images derived from four
independent experiments in which the cells were separately transfected with the
BiFC constructs. Bars, 10 lm. (B) HEK293 cells co-expressing TrkA-VN and TrkA-VC
were treated with (+) or without () 10 lg/ml BFA. The cells were ﬁxed, and
immunostained with anti-calnexin antibody and then with ﬂuorescently labeled
secondary antibody. Note that Venus ﬂorescence of the plasma membrane is not
observed in cells treated with BFA. This ﬁgure represents at least 14 similar images
derived from two independent experiments in which the cells were separately
transfected twice with the BiFC constructs. Bars, 10 lm.
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only in the plasma membrane but also inside the cells. The level
of receptor homodimers inside the cells was much higher than that
in the plasma membrane. This is consistent with the results above
that only a small fraction of TrkA was chemically crosslinked with
the membrane-impermeable crosslinker (Fig. 1). The TrkA ex-
pressed inside the cells is homodimeric since the receptors pro-
duced ﬂuorescence due to BiFC, but are inactive since they were
not phosphorylated before NGF stimulation (Fig. 2A, middle).
These results suggested that the TrkA receptor might dimerize be-
fore reaching the cell surface. To examine this possibility, we trea-
ted cells co-expressing TrkA-VN and TrkA-VC with BFA, a lactone
antibiotic that disassembles the Golgi apparatus and blocks anter-
ograde transport of membrane proteins from ER to Golgi [24]. In
the presence of BFA, Venus ﬂuorescence was clearly observed in-
side the cells (Fig. 2B), mainly co-localized with calnexin, an ER
marker, indicating that TrkA spontaneously dimerizes in ER before
the newly synthesized receptor reaches the cell surface.
3.3. Preformed TrkA homodimers observed by luciferase fragment
complementation
Since the interaction of the BiFC fragments is irreversible, we
cannot determine the ratio of the TrkA dimer and monomer at
equilibrium. Therefore, we employed ﬁreﬂy luciferase fragment
complementation since the interaction between the luciferase frag-
ments is reversible [25]. We fused the N-terminal or C-terminal
fragment of ﬁreﬂy luciferase to the C-terminus of TrkA. Western
blotting of cells expressing the fusion receptor TrkA-NLuc or
TrkA-CLuc revealed that the fusion molecule was phosphorylated Luc
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 EGFR-NLuc/
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Fig. 3. Luciferase fragment complementation assay of TrkA homodimers. (A)
HEK293 cells expressing indicated protein(s) were cultured in a microtiter plate,
and then incubated with luciferin. The cells’ bioluminescence imaging and relative
bioluminescence intensities are shown on the left and right, respectively. ⁄⁄P < 0.01.
(B) HEK293 cells expressing a full-length luciferase (Luc) or co-expressing TrkA-
NLuc and TrkA-CLuc were incubated with or without NGF as indicated, and their
bioluminescence intensities were measured. Data are the mean ± S.D. of three
independent results.upon NGF binding (Supplementary Fig. S2). This result demon-
strates that the fusion receptors are intact in terms of ligand-
induced phosphorylation of the fusion receptors.
When HEK293 cells co-expressing TrkA-NLuc and TrkA-CLuc
were incubated with luciferin, bioluminescence was clearly de-
tected as shown in Fig. 3A. This result demonstrates that the fusion
receptors have homodimeric structures although the biolumines-
cence level was lower than that of cells expressing pGL3, which en-
codes a full-length ﬁreﬂy luciferase. By contrast, very low levels of
bioluminescence were detected in HEK293 cells co-expressing
TrkA-NLuc and EGFR-CLuc, or TrkA-CLuc and EGFR-NLuc as nega-
tive controls. The bioluminescence levels produced by cells co-
expressing TrkA-NLuc and TrkA-CLuc were higher than those of
cells co-expressing EGFR-NLuc and EGFR-CLuc, fusion proteins of
the human epidermal growth factor receptor (EGFR). It has been
demonstrated by a number of studies that EGFR on the cell surface
has a dimeric structure prior to ligand binding [14,26–30]. There-
fore, cells co-expressing EGFR-NLuc and EGFR-CLuc were also used
as positive controls in this assay. The bioluminescence intensity of
cells co-expressing TrkA-NLuc and TrkA-CLuc was higher than that
of cells co-expressing EGFR-NLuc and EGFR-CLuc, conﬁrming that
TrkA spontaneously dimerizes like EGFR. Furthermore, the
bioluminescence intensity of cells co-expressing TrkA-NLuc and
TrkA-CLuc was not inﬂuenced by its ligand binding (Fig. 3B), dem-
onstrating that the majority of TrkA molecules have dimeric
structures, irrespective of ligand binding.4. Discussion
We have shown that preformed TrkA dimers exist in living cells
prior to ligand binding by using three different approaches. At ﬁrst,
we analyzed the preformed TrkA dimers by chemical crosslinking,
and found that a small fraction of TrkA was crosslinked in the ab-
sence of NGF. Furthermore, this crosslinkable fraction was not in-
creased upon NGF binding, indicating that the dimers of TrkA are
not induced by the ligand. Secondly, we employed BiFC to observe
the preformed dimers in living cells. The results indicate that new-
ly formed TrkA dimerizes in the ER before reaching the cell surface,
and a large fraction of TrkA molecules exist inside the cell. Thirdly,
bioluminescence intensity due to the luciferase fragment comple-
mentation was not enhanced at all by NGF treatment, indicating
that the majority of TrkA has a homodimeric structure. Thus, all
the results obtained from the three distinct approaches demon-
strate that most of the TrkA receptors exist as preformed, yet inac-
tive, dimers in living cells.
It is believed that TrkA is activated through its dimerization in-
duced by NGF binding. This model was based on studies in which
chemical crosslinking detected TrkA homodimers only in the pres-
ence of NGF [4,5], and was also based on the dimeric structure of
the ligand NGF, which has two symmetric receptor binding sites
[7]. In the crosslinking studies, it was shown by autoradiography
that [125I] NGF bound both TrkA monomers and dimers. These re-
sults cannot rule out the possibility that the TrkA receptors exist as
preformed dimers in the absence of NGF, since the receptor homo-
dimers could not be visualized. As described above, furthermore, it
was previously reported that the artiﬁcial ligand molecules with an
asymmetric structure can activate TrkA, suggesting that ligand-
induced homodimerization is not necessary for the receptor activa-
tion [9–11]. It was also found that TrkA expressed in Xenopus
oocytes has an oligomeric structure in the absence of NGF [12].
These results are consistent with our results shown above, and
support that TrkA exists as a dimer in living cells in the absence
of ligand. Indeed, an increasing number of studies indicate that
many membrane receptors, which were thought to be activated
by ligand-induced dimerization, have recently been demonstrated
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living cells. These include EGFR [14,26–30], erythropoietin recep-
tor [31], growth hormone receptor (GHR) [32,33], and Toll-like
receptor-9 [34]. It has recently been shown that the transmem-
brane domains of many receptor tyrosine kinases including TrkA
have an intrinsic property to form stable dimeric structures within
a membrane [35]. Furthermore, it has been shown that the intra-
cellular domains play a major role in the spontaneous dimerization
of the EGF (ErbB) receptors [14,27]. In the case of EGFR and GHR, it
has also been proposed that ligand binding is likely to induce the
rotation/twist of the transmembrane domains of the preformed
receptor dimers, resulting in rearrangement of the cytoplasmic do-
mains for activation [14,26,34]. Further investigation of structures
of the Trk receptor family will shed light on molecular mechanisms
underlying the receptor activation.
Acknowledgements
We thank Garret M. Brodeur for providing us with pLNCX/
hTrkA, David Piwnica-Worms for FRB-Nluc and CLuc-FKBP, and
Hiraku Miyagi for EGFR-NLuc and EGFR-CLuc.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.12.031.
References
[1] Kaplan, D.R. and Miller, F.D. (2000) Neurotrophin signal transduction in the
nervous system. Curr. Opin. Neurobiol. 10, 381–391.
[2] Chao, M.V. (2003) Neurotrophins and their receptors: a convergence point for
many signalling pathways. Nat. Rev. Neurosci. 4, 299–309.
[3] Simi, A. and Ibáñez, C.F. (2010) Assembly and activation of neurotrophic factor
receptor complexes. Dev. Neurobiol. 70, 323–331.
[4] Meakin, S.O. and Shooter, E.M. (1991) Molecular investigations on the high-
afﬁnity nerve growth factor receptor. Neuron 6, 153–163.
[5] Jing, S., Tapley, P. and Barbacid, M. (1992) Nerve growth factor mediates signal
transduction through trk homodimer receptors. Neuron 9, 1067–1079.
[6] McDonald, N.Q., Lapatto, R., Murray-Rust, J., Gunning, J., Wlodawer, A. and
Blundell, T.L. (1991) New protein fold revealed by a 2.3-Å resolution crystal
structure of nerve growth factor. Nature 354, 411–414.
[7] Ibáñez, C.F., Ilag, L.L., Murray-Rust, J. and Persson, H. (1993) An extended
surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the
engineering of a multifunctional pan-neurotrophin. EMBO J. 12, 2281–2293.
[8] Wiesmann, C., Ultsch, M.H., Bass, S.H. and de Vos, A.M. (1999) Crystal structure
of nerve growth factor in complex with the ligand-binding domain of the TrkA
receptor. Nature 401, 184–188.
[9] Maliartchouk, S., Debeir, T., Beglova, N., Cuello, A.C., Gehring, K. and Saragovi,
H.U. (2000) Genuine monovalent ligands of TrkA nerve growth factor
receptors reveal a novel pharmacological mechanism of action. J. Biol. Chem.
275, 9946–9956.
[10] Maliartchouk, S., Feng, Y., Ivanisevic, L., Debeir, T., Cuello, A.C., Burgess, K. and
Saragovi, H.U. (2007) A designed peptidomimetic agonistic ligand of TrkA
nerve growth factor receptors. Mol. Pharmacol. 57, 385–391.
[11] Treanor, J.J.S., Schmelzer, C., Knusel, B., Winslow, J.W., Shelton, D.L., Hefti, F.,
Nikolics, K. and Burton, L.E. (1995) Heterodimeric neurotrophins induce
phosphorylation of Trk receptors and promote neuronal differentiation in
PC12 cells. J. Biol. Chem. 270, 23104–23110.
[12] Mischel, P.S., Umbach, J.A., Eskandari, S., Smith, S.G., Gundersen, C.B. and
Zampighi, G.A. (2002) Nerve growth factor signals via preexisting TrkA
receptor oligomers. Biophys. J. 83, 968–976.
[13] Shyu, Y.J., Liu, H., Deng, X. and Hu, C.D. (2006) Identiﬁcation of new ﬂuorescent
protein fragments for bimolecular ﬂuorescence complementation analysis
under physiological conditions. BioTechniques 40, 61–66.[14] Tao, R.H. and Maruyama, I.N. (2008) All EGF (ErbB) receptors have preformed
homo- and heterodimeric structures in living cells. J. Cell Sci. 121, 3207–3217.
[15] Eggert, A., Ikegaki, N., Liu, X.-G., Chou, T.T., Lee, V.M., Trojanowski, J.Q. and
Brodeur,G.M. (2000)Moleculardissectionof TrkAsignal transductionpathways
mediating differentiation in human neuroblastoma cells. Oncogene 19, 2043–
2051.
[16] Eggert, A., Grotzer, M.A., Ikegaki, N., Liu, X.-G., Evans, A.E. and Brodeur, G.M.
(2002) Expression of the neurotrophin receptor TrkA down-regulates
expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma
cells. Cancer Res. 62, 1802–1808.
[17] Yan, C., Liang, Y., Nylander, K.D. and Schor, N.F. (2002) TrkA as a life and death
receptor: receptor dose as a mediator of function. Cancer Res. 62, 4867–4875.
[18] Daukas, G. and Zigmond, S.H. (1985) Inhibition of receptor-mediated but not
ﬂuid-phase endocytosis in polymorphonuclear leukocytes. J. Cell Biol. 101,
1673–1679.
[19] Heuser, J.E. and Anderson, R.G.W. (1989) Hypertonic media inhibit receptor-
mediated endocytosis by blocking clathrin-coated pit formation. J. Cell Biol.
108, 389–400.
[20] Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T. and Barbacid, M. (1989)
Molecular and biochemical characterization of the human trk proto-oncogene.
Mol. Cell. Biol. 9, 24–33.
[21] Jullien, J., Guili, V., Reichardt, L.F. and Rudkin, B.B. (2002) Molecular kinetics of
nerve growth factor receptor trafﬁcking and activation. J. Biol. Chem. 277,
38700–38708.
[22] Hu, C.D., Chinenov, Y. and Kerppola, T.K. (2002) Visualization of interactions
among bZIP and Rel family proteins in living cells using bimolecular
ﬂuorescence complementation. Mol. Cell 9, 789–798.
[23] Nagai, T., Ibata, K., Park, E.S., Kubota, M., Mikoshiba, K. and Miyawaki, A. (2002)
A variant of yellow ﬂuorescent protein with fast and efﬁcient maturation for
cell-biological applications. Nat. Biotechnol. 20, 87–90.
[24] Fujiwara, T., Oda, K., Yokota, S., Takatsuki, A. and Ikehara, Y. (1988) Brefeldin A
causes disassembly of the Golgi complex and accumulation of secretory
proteins in the endoplasmic reticulum. J. Biol. Chem. 263, 18545–18552.
[25] Luker, K.E., Smith, M.C.P., Luker, G.D., Gammon, S.T., Piwnica-Worms, H. and
Piwnica-Worms, D. (2004) Kinetics of regulated protein-protein interactions
revealed with ﬁreﬂy luciferase complementation imaging in cells and living
animals. Proc. Natl. Acad. Sci. USA 101, 12288–12293.
[26] Moriki, T., Maruyama, H. and Maruyama, I.N. (2001) Activation of preformed
EGF receptor dimers by ligand-induced rotation of the transmembrane
domain. J. Mol. Biol. 311, 1011–1026.
[27] Yu, X., Sharma, K.D., Takahashi, T., Iwamoto, R. and Mekada, E. (2002) Ligand-
independent dimer formation of epidermal growth factor receptor (EGFR) is a
step separable from ligand-induced EGFR signaling. Mol. Biol. Cell 13, 2547–
2557.
[28] Martin-Fernandez, M., Clarke, D.T., Tobin, M.J., Jones, S.V. and Jones, G.R.
(2002) Preformed oligomeric epidermal growth factor receptors undergo an
ectodomain structure change during signaling. Biophys. J. 82, 2415–2427.
[29] Clayton, A.H.A., Walker, F., Orchard, S.G., Henderson, C., Fuchs, D., Rothacker, J.,
Nice, E.C. and Burgess, A.W. (2005) Ligand-induced dimer-tetramer transition
during the activation of the cell surface epidermal growth factor receptor-A
multidimensional microscopy analysis. J. Biol. Chem. 280, 30392–30399.
[30] Liu, P., Sudhaharan, T., Koh, R.M.L., Hwang, L.C., Ahmed, S., Maruyama, I.N. and
Wohland, T. (2007) Investigation of the dimerization of proteins from the
epidermal growth factor receptor family by single wavelength ﬂuorescence
cross-correlation spectroscopy. Biophys. J. 93, 684–698.
[31] Constantinescu, S.N., Keren, T., Socolovsky, M., Nam, H., Henis, Y.I. and Lodish,
H.F. (2001) Ligand-independent oligomerization of cell-surface erythropoietin
receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. USA
98, 4379–4384.
[32] Gent, J., van Kerkhof, P., Roza, M., Bu, G. and Strous, G.J. (2002) Ligand-
independent growth hormone receptor dimerization occurs in the
endoplasmic reticulum and is required for ubiquitin system-dependent
endocytosis. Proc. Natl. Acad. Sci. USA 99, 9858–9863.
[33] Brown, R.J., Adams, J.J., Pelekanos, R.A., Wan, Y., McKinstry, W.J., Palethorpe, K.,
Seeber, R.M., Monks, T.A., Eidne, K.A., Parker, M.W. and Waters, M.J. (2005)
Model for growth hormone receptor activation based on subunit rotation
within a receptor dimer. Nat. Struct. Mol. Biol. 12, 814–821.
[34] Latz, E., Verma, A., Visintin, A., Gong, M., Sirois, C.M., Klein, D.C.G., Monks, B.G.,
McKnight, C.J., Lamphier, M.S., Duprex, W.P., Espevik, T. and Golenbock, D.T.
(2007) Ligand-induced conformational changes allosterically activate Toll-like
receptor 9. Nat. Immunol. 8, 772–779.
[35] Finger, C., Escher, C. and Schneider, D. (2009) The single transmembrane
domains of human receptor tyrosine kinases encode self-interactions. Sci.
Signal. 2, ra56.
